Indeed we confirmed a strong up-regulation of Anxa2 in angiogenic xenografts compared to invasive ones, as well as a significant increase in Anxa2 expression in high grade gliomas (grade III and IV) compared to low grades (grade I and II) [9]. This evidence concerns the gene ANXA2 and central nervous system cancer.